JP2010535214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535214A5 JP2010535214A5 JP2010519939A JP2010519939A JP2010535214A5 JP 2010535214 A5 JP2010535214 A5 JP 2010535214A5 JP 2010519939 A JP2010519939 A JP 2010519939A JP 2010519939 A JP2010519939 A JP 2010519939A JP 2010535214 A5 JP2010535214 A5 JP 2010535214A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- difluoro
- benzamide
- thiophen
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004310 Ion Channels Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- QVBMLLKABAKUEC-UHFFFAOYSA-N 2,6-difluoro-n-[4-(3-methyl-5-pyridin-3-ylthiophen-2-yl)phenyl]benzamide Chemical compound CC=1C=C(C=2C=NC=CC=2)SC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F QVBMLLKABAKUEC-UHFFFAOYSA-N 0.000 claims 1
- VURDERBCIUUPJU-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)thiophen-3-yl]phenyl]benzamide Chemical compound CC=1SC(C=2OC=NN=2)=CC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F VURDERBCIUUPJU-UHFFFAOYSA-N 0.000 claims 1
- NBKIOHYCZNRTAF-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(4-methylpyridin-3-yl)thiophen-3-yl]phenyl]benzamide Chemical compound CC=1SC(C=2C(=CC=NC=2)C)=CC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F NBKIOHYCZNRTAF-UHFFFAOYSA-N 0.000 claims 1
- BJUPEDBRBVKQIK-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-(1h-imidazol-5-yl)-2-methylthiophen-3-yl]phenyl]benzamide Chemical compound CC=1SC(C=2NC=NC=2)=CC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F BJUPEDBRBVKQIK-UHFFFAOYSA-N 0.000 claims 1
- UVGPFCQXXQFXLB-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-(4-methoxypyridin-3-yl)-2-methylthiophen-3-yl]phenyl]benzamide Chemical compound COC1=CC=NC=C1C1=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C(C)S1 UVGPFCQXXQFXLB-UHFFFAOYSA-N 0.000 claims 1
- SLWNYRLLIBVJIG-UHFFFAOYSA-N 2,6-difluoro-n-[5-[2-methyl-5-(3-methylimidazol-4-yl)thiophen-3-yl]pyrazin-2-yl]benzamide Chemical compound CC=1SC(C=2N(C=NC=2)C)=CC=1C(N=C1)=CN=C1NC(=O)C1=C(F)C=CC=C1F SLWNYRLLIBVJIG-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 208000015338 Autoimmune hepatitis type 1 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- IFPYPNKQKUNWRX-UHFFFAOYSA-O CC([S+](C=C1)C2=CN=CN2)=C1C(N=C1)=CN=C1C(C=CC(F)=C1C(N)=O)=C1F Chemical compound CC([S+](C=C1)C2=CN=CN2)=C1C(N=C1)=CN=C1C(C=CC(F)=C1C(N)=O)=C1F IFPYPNKQKUNWRX-UHFFFAOYSA-O 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010996 Corneal degeneration Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010058141 Skin graft rejection Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 208000024035 chronic otitis media Diseases 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- BMJSTMBWWGUHHZ-UHFFFAOYSA-N n-[4-[5-(3-ethylimidazol-4-yl)-2-methylthiophen-3-yl]phenyl]-2,6-difluorobenzamide Chemical compound CCN1C=NC=C1C1=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C(C)S1 BMJSTMBWWGUHHZ-UHFFFAOYSA-N 0.000 claims 1
- BQQBYVPSZVQMPN-UHFFFAOYSA-N n-[4-[5-(4-chloropyridin-3-yl)-2-methylthiophen-3-yl]phenyl]-2,6-difluorobenzamide Chemical compound CC=1SC(C=2C(=CC=NC=2)Cl)=CC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F BQQBYVPSZVQMPN-UHFFFAOYSA-N 0.000 claims 1
- VRMUJAXIEMIPOU-UHFFFAOYSA-N n-[4-[5-(5-chloro-2-methoxypyridin-3-yl)-2-methylthiophen-3-yl]phenyl]-2,6-difluorobenzamide Chemical compound COC1=NC=C(Cl)C=C1C1=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C(C)S1 VRMUJAXIEMIPOU-UHFFFAOYSA-N 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- -1 aminophenyl Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000001246 bromo group Chemical class Br* 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- LNYYVHNIHCOWCB-UHFFFAOYSA-N 2-methylpyridine-4-carbonyl chloride Chemical compound CC1=CC(C(Cl)=O)=CC=N1 LNYYVHNIHCOWCB-UHFFFAOYSA-N 0.000 description 1
- HETSCJCZMZWQMJ-UHFFFAOYSA-N 3-methyl-n-[4-(3-methyl-5-pyrimidin-5-ylthiophen-2-yl)phenyl]pyridine-4-carboxamide Chemical compound CC=1C=C(C=2C=NC=NC=2)SC=1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C HETSCJCZMZWQMJ-UHFFFAOYSA-N 0.000 description 1
- PHKSPGLTXLMXIN-UHFFFAOYSA-N 5-(4-methylthiophen-2-yl)pyrimidine Chemical compound CC1=CSC(C=2C=NC=NC=2)=C1 PHKSPGLTXLMXIN-UHFFFAOYSA-N 0.000 description 1
- YYTDZXLXMXLZKN-UHFFFAOYSA-N 5-(5-bromo-4-methylthiophen-2-yl)pyrimidine Chemical compound S1C(Br)=C(C)C=C1C1=CN=CN=C1 YYTDZXLXMXLZKN-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- NTNLWSYOFAXBGI-UHFFFAOYSA-N methyl 4-[4-[(2,6-difluorobenzoyl)amino]phenyl]-5-methylthiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1C NTNLWSYOFAXBGI-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96282407P | 2007-08-01 | 2007-08-01 | |
| US60/962,824 | 2007-08-01 | ||
| PCT/US2008/009305 WO2009017818A1 (en) | 2007-08-01 | 2008-07-31 | Heterocycle-aryl compounds for inflammation and immune-related uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535214A JP2010535214A (ja) | 2010-11-18 |
| JP2010535214A5 true JP2010535214A5 (enExample) | 2012-10-04 |
| JP5511664B2 JP5511664B2 (ja) | 2014-06-04 |
Family
ID=40304688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519939A Expired - Fee Related JP5511664B2 (ja) | 2007-08-01 | 2008-07-31 | 炎症および免疫関連用途のための複素環−アリール化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8435996B2 (enExample) |
| EP (1) | EP2184994B1 (enExample) |
| JP (1) | JP5511664B2 (enExample) |
| CA (1) | CA2695143A1 (enExample) |
| ES (1) | ES2440267T3 (enExample) |
| TW (1) | TWI444186B (enExample) |
| WO (1) | WO2009017818A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006081389A1 (en) | 2005-01-25 | 2006-08-03 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
| CA2640090A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| WO2007087442A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
| CA2640091A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| AU2007227210A1 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| AU2009300317A1 (en) | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| AU2010321832B2 (en) | 2009-11-20 | 2014-08-14 | Amgen Inc. | Anti-Orai1 antigen binding proteins and uses thereof |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2563759B1 (en) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| HUE029570T2 (en) | 2010-04-27 | 2017-03-28 | Calcimedica Inc | Intracellular calcium modifying compounds |
| CN103180316A (zh) | 2010-08-27 | 2013-06-26 | 钙医学公司 | 调节细胞内钙的化合物 |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9856240B2 (en) | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
| CN114712513B (zh) | 2015-02-27 | 2026-02-10 | 钙医学公司 | 胰腺炎治疗 |
| AU2016306301B2 (en) | 2015-08-07 | 2021-02-11 | Calcimedica, Inc. | Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury |
| CN113557020A (zh) | 2018-09-14 | 2021-10-26 | 瑞真药业公司 | 包含crac抑制剂和皮质类固醇的组合物及其使用方法 |
| CA3167339A1 (en) | 2020-01-13 | 2021-07-22 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| US12544371B2 (en) | 2020-03-20 | 2026-02-10 | Calcimedica, Inc. | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome |
| GB202006076D0 (en) * | 2020-04-24 | 2020-06-10 | Univ Greenwich | Interleukin inhibitors |
| US12522589B2 (en) | 2020-11-13 | 2026-01-13 | Calcimedica, Inc. | Synthesis of CRAC channel inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| US8518950B2 (en) | 2005-01-25 | 2013-08-27 | Synta Pharmaceuticals Corp. | 2-amido pyrazines for inflammation and immune related uses |
| EP1895898B1 (en) | 2005-06-29 | 2011-02-16 | Compumedics Limited | Sensor assembly with conductive bridge |
| CA2639913A1 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceutical Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
-
2008
- 2008-07-31 TW TW097128954A patent/TWI444186B/zh not_active IP Right Cessation
- 2008-07-31 CA CA2695143A patent/CA2695143A1/en not_active Abandoned
- 2008-07-31 ES ES08794963.2T patent/ES2440267T3/es active Active
- 2008-07-31 EP EP08794963.2A patent/EP2184994B1/en not_active Not-in-force
- 2008-07-31 US US12/452,979 patent/US8435996B2/en not_active Expired - Fee Related
- 2008-07-31 JP JP2010519939A patent/JP5511664B2/ja not_active Expired - Fee Related
- 2008-07-31 WO PCT/US2008/009305 patent/WO2009017818A1/en not_active Ceased
-
2013
- 2013-04-03 US US13/855,803 patent/US20130236481A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535218A5 (enExample) | ||
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2010535215A5 (enExample) | ||
| JP2010509342A5 (enExample) | ||
| JP2012504605A5 (enExample) | ||
| US10399967B2 (en) | Compounds for inflammation and immune-related uses | |
| CA2595855C (en) | Pyrazine compounds for inflammation and immune-related uses | |
| JP4575918B2 (ja) | ４−アリル−ニコチンアミド誘導体の製造方法 | |
| US20040186290A1 (en) | Tri(cyclo) substituted amide glucokinase activator compounds | |
| MX2010013058A (es) | Derivado de benceno o tiofeno y su uso como inhibidor de proteina 1 de adhesion vascular. | |
| JP2008513508A5 (enExample) | ||
| CA2640090A1 (en) | Substituted aromatic compounds for inflammation and immune-related uses | |
| JP4669839B2 (ja) | ジフェニルピリジン誘導体、その製造法および治療用途 | |
| WO2005009539A2 (en) | Compounds for inflammation and immune-related uses | |
| TW200800188A (en) | Pyridylphenyl compounds for inflammation and immune-related uses | |
| AU2007227210A1 (en) | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses | |
| JP2009524677A (ja) | 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 | |
| JP2008526866A (ja) | 炎症及び免疫に関連する用途に用いる化合物 | |
| WO2013062065A1 (ja) | アミノアルキル置換n-チエニルベンズアミド誘導体 | |
| JP2012524107A5 (enExample) | ||
| US9206136B2 (en) | Pyrazolyl-based carboxamides I | |
| JP2019520317A (ja) | ベンゾイルグリシン誘導体およびその作製および使用の方法 | |
| US5847123A (en) | Imide derivatives for inhibiting the production of interleukin-1β and the production of tumor necrosis factor α | |
| JPWO2004074260A1 (ja) | ピリミジン誘導体 | |
| US20140242099A1 (en) | Compounds for inflammation and immune-related uses |